370 Comparison of 3x Weekly vs Daily Administration of Oral Cinacalcet for the Control of Secondary Hyperparathyroidism (SHPT) in Patients Receiving Hemodialysis (HD)
Publication date: April 2020Source: American Journal of Kidney Diseases, Volume 75, Issue 4Author(s): (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - March 18, 2020 Category: Urology & Nephrology Source Type: research

Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
We examined standard laboratory parameters of patients on in-center hemodialysis receiving intravenous vitamin D who switched to oral calcitriol. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective cohort study of adult patients treated within Fresenius Kidney Care clinics. During a 6-month period (December 2013 to May 2014), we identified patients on an intravenous vitamin D analog (doxercalciferol or paricalcitol) who switched to oral calcitriol and matched them to patients receiving an intravenous vitamin D analog. Mean serum calcium, phosphate, and intact parathyroid hormone (iPTH) conc...
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 28, 2020 Category: Urology & Nephrology Authors: Thadhani RI, Rosen S, Ofsthun NJ, Usvyat LA, Dalrymple LS, Maddux FW, Hymes JL Tags: Clin J Am Soc Nephrol Source Type: research

Primary Hyperparathyroidism Manifesting with Severe Hypercalcemia in a Nonagenarian Man: Pitfall of Common Imaging Techniques, Localization by 18F-Choline Positron Emission Tomography/Computed Tomography and Successful Management with Calcimimetics.
Authors: Foppiani L, Bottoni G, Piccardo A Abstract A nonagenarian hypertensive man with chronic kidney disease (CKD) was admitted to the emergency department for gastrointestinal symptoms and worsening symptoms of depression. Severe hypercalcemia (15.3 mg/dL) was found and he was hospitalized. Fluids, loop diuretics and glucocorticoids were administered intravenously, which partially reduced calcium levels over a few days and improved his clinical condition. PTH levels proved increased (306 pg/mL) and 25-OHD levels were reduced; primary hyperparathyroidism (PHPT) was diagnosed. Neck ultrasonography (USG) did not s...
Source: Acta Medica: Hradec Kralove - February 11, 2020 Category: General Medicine Tags: Acta Medica (Hradec Kralove) Source Type: research

Early Response of the Parathyroid Gland to Withdrawal of a Calcimimetic Compound in Uremic Rats.
We examined the response of parathyroid glands to withdrawal of cinacalcet in uremic rats. Uremic rats were fed a high phosphate diet to develop secondary hyperparathyroidism (SHPT) and then divided into groups treated with vehicle (UC), cinacalcet (Cina), and cinacalcet and maxacalcitol (Maxa), a vitamin D receptor activator (VDRA) (Cina+Maxa). After 2 weeks treatment, vehicle and cinacalcet were withdrawn, while Maxa was continued. Rats were analyzed immediately (day 0) and 7 days (day 7) after withdrawal. The Cina and Cina+Maxa had significantly lower PTH than the UC on day 0, but PTH in the Cina reached UC levels on da...
Source: Am J Physiol Renal P... - January 21, 2020 Category: Urology & Nephrology Authors: Mizobuchi M, Ogata H, Koiwa F, Honda H Tags: Am J Physiol Renal Physiol Source Type: research

Cinacalcet treatment experience in hereditary vitamin D resistant rickets
Journal Name: Journal of Pediatric Endocrinology and Metabolism Issue: Ahead of print (Source: Journal of Pediatric Endocrinology and Metabolism)
Source: Journal of Pediatric Endocrinology and Metabolism - January 12, 2020 Category: Endocrinology Source Type: research

Cinacalcet treatment experience in hereditary vitamin D resistant rickets
Journal Name: Journal of Pediatric Endocrinology and Metabolism Volume: 33 Issue: 2 Pages: 313-318 (Source: Journal of Pediatric Endocrinology and Metabolism)
Source: Journal of Pediatric Endocrinology and Metabolism - January 11, 2020 Category: Endocrinology Source Type: research

Severe peripheral arterial diseases in hemodialysis patient: A case report
Rationale: Peripheral arterial diseases (PADs) is defined as a systemic arterial disorders involving the lower extremity arteries, iliac, and carotid, which is developed more common in patients with chronic kidney disease (CKD) than individual with normal renal function. Concurrence of mesenteric artery disease and lower extremity artery disease (LEAD) is rare. The presence of PADs in patients receiving hemodialysis leads to a dramatic increase in risk of cardiovascular mortality. However, the early diagnosis of PADs in patient with CKD remains a challenge to nephrologists, which adds an adverse effect on prognosis. Pat...
Source: Medicine - January 1, 2020 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.
CONCLUSION: Two-thirds of cinacalcet initiated patients experienced hypocalcaemia with 9% being severe. Hypocalcemia was mostly asymptomatic, transient (with and without targeted intervention to correct it) and not associated with an increase in cardiovascular events or deaths. PMID: 31848883 [PubMed - as supplied by publisher] (Source: Journal of Nephrology)
Source: Journal of Nephrology - December 17, 2019 Category: Urology & Nephrology Authors: Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J Tags: J Nephrol Source Type: research

Calcium sensing receptor activation in THP-1 macrophages triggers NLRP3 inflammasome and human preadipose cell inflammation
Publication date: Available online 15 November 2019Source: Molecular and Cellular EndocrinologyAuthor(s): Amanda D'Espessailles, Natalia Santillana, Sofía Sanhueza, Cecilia Fuentes, Mariana CifuentesAbstractExcess adipose tissue (AT) associates with inflammation and obesity-related diseases. We studied whether calcium-sensing receptor (CaSR)-mediated NLRP3 inflammasome activation in THP-1 macrophages elevates inflammation in LS14 preadipocytes, modeling deleterious AT cell crosstalk. THP-1 macrophages exposed to Cinacalcet (CaSR activator, 2 μM, 4 h) showed elevated proinflammatory marker and NLRP3 inflammaso...
Source: Molecular and Cellular Endocrinology - November 15, 2019 Category: Endocrinology Source Type: research

Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease
ConclusionThe parathyroid oxyphil cell proportion was associated with preoperative PTH and total weight of removed parathyroid glands in the patients with CKD. Patients with more parathyroid oxyphil proportion had lower preoperative PTH level and smaller total weight of the removed parathyroid glands. (Source: International Urology and Nephrology)
Source: International Urology and Nephrology - November 4, 2019 Category: Urology & Nephrology Source Type: research

Thoracic Deformity and Acro-Osteolysis in Severe Renal Osteodystrophy
A 29-year-old El Salvadoran man with a history of end-stage renal disease (ESRD) from an unknown cause since the age of 21 and multiple dialysis-catheter associated infections and thrombosis, was admitted to the hospital with diffuse chest discomfort, body aches, and fever. He was undergoing 3-times-weekly hemodialysis and was being treated for secondary hyperparathyroidism with sevelamer, vitamin D analogs, and cinacalcet for the past few years. On inspection, he was short statured, measuring 4 feet and 5 inches in height, his rib cage was deformed, and he had bulbous fingertips with shortened distal phalanges on both han...
Source: Mayo Clinic Proceedings - November 1, 2019 Category: Internal Medicine Authors: Rukma Govindu, Hussam Ammar Tags: Medical image Source Type: research

X-linked Hypophosphatemic Rickets: the Challenges of Treatment
AbstractX-linked dominant hypophosphatemic rickets (XLHR) is the most common inherited form of rickets due to a mutation in the phosphate regulating gene with homologies to endopeptidases on the X chromosome (PHEX gene) expressed in bones and teeth. This leads to impaired renal reabsorption of phosphate and defective bone mineralization. Clinical presentation often occurs in childhood, where children mostly present with bow legs, delayed walking, or gait difficulties. Other clinical features may also be present and these are described in this review in addition to the classic laboratory findings. Focus is made on the manag...
Source: Clinical Reviews in Bone and Mineral Metabolism - October 29, 2019 Category: Internal Medicine Source Type: research

Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR).
Authors: Chavez-Abiega S, Mos I, Centeno PP, Elajnaf T, Schlattl W, Ward DT, Goedhart J, Kallay E Abstract The calcium-sensing receptor (CaSR) is a G protein-coupled receptor that plays a key role in calcium homeostasis, by sensing free calcium levels in blood and regulating parathyroid hormone secretion in response. The CaSR is highly expressed in parathyroid gland and kidney where its role is well characterised, but also in other tissues where its function remains to be determined. The CaSR can be activated by a variety of endogenous ligands, as well as by synthetic modulators such as Cinacalcet, used in the clin...
Source: Advances in Experimental Medicine and Biology - October 26, 2019 Category: Research Tags: Adv Exp Med Biol Source Type: research

Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR
AbstractFamilial hypocalciuric hypercalcemia (FHH) is a benign autosomal dominant condition characterized by lifelong asymptomatic hypercalcemia. FHH is typically caused by a heterozygous inactivating mutation of the calcium-sensing receptor (CaSR) and characterized by moderate hypercalcemia, inappropriately normal or elevated serum parathyroid hormone (PTH), and relative hypocalciuria (FeCa  2%. PTH levels were repeatedly below the mean of the reference range (on two separate assays) and sometimes even below the lower reference limit. Two siblings, one niece, and her son had hypercalcemia without nephrolithiasis. C...
Source: Osteoporosis International - October 23, 2019 Category: Orthopaedics Source Type: research

Interventions for preventing bone disease in kidney transplant recipients.
CONCLUSIONS: Bisphosphonate therapy may reduce fracture and bone pain after kidney transplantation, however low certainty in the evidence indicates it is possible that treatment may make little or no difference. It is uncertain whether bisphosphonate therapy or other bone treatments prevent other skeletal complications after kidney transplantation, including spinal deformity or avascular bone necrosis. The effects of bone treatment for children and adolescents after kidney transplantation are very uncertain. PMID: 31637698 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - October 22, 2019 Category: General Medicine Authors: Palmer SC, Chung EY, McGregor DO, Bachmann F, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research

Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years 
.
Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years
. Clin Nephrol. 2019 Oct 07;: Authors: Joseph C, Shah S, Geer J, Juarez-Calderon M, Srivaths PR, Swartz SJ Abstract BACKGROUND: Management of chronic kidney disease mineral bone disorder (CKD-MBD) in pediatric patients with end-stage renal disease (ESRD) is challenging. While the use of calcimimetics is well-studied in adults on dialysis, few studies have been performed in pediatrics. Little is known about the use of cinacalcet in young children with ESRD. The aim of this study was to report the effica...
Source: Clinical Nephrology - October 7, 2019 Category: Urology & Nephrology Authors: Joseph C, Shah S, Geer J, Juarez-Calderon M, Srivaths PR, Swartz SJ Tags: Clin Nephrol Source Type: research

Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials
AbstractBackgroundSecondary hyperparathyroidism (SHPT) is a common and serious complication of chronic kidney disease, particularly in end-stage renal disease. Currently, both cinacalcet and vitamin D are used to treat SHPT via two different mechanisms, but it is still unclear whether the combination use of these two drugs can be a safe and effective alternative to vitamin D alone. Therefore, the aim of this meta-analysis was to assess the efficacy and safety of cinacalcet plus vitamin D in the treatment of SHPT.MethodsFour electronic databases, including PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENT...
Source: International Urology and Nephrology - September 17, 2019 Category: Urology & Nephrology Source Type: research

Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma.
In conclusion, preoperative restoration of low 25OHD levels is essential for prevention of HBS. Postoperative treatment with active metabolites of vitamin D must be initiated as early as possible, in order to prevent or minimize the development of HBS, and to reduce the duration of hospitalization. PMID: 31475947 [PubMed - in process] (Source: Journal of Musculoskeletal Neuronal Interactions)
Source: Journal of Musculoskeletal Neuronal Interactions - September 3, 2019 Category: Neurology Tags: J Musculoskelet Neuronal Interact Source Type: research

Successful management of tertiary hyperparathyroidism associated with hypophosphataemic rickets in an adult.
We report a case of THP, which developed during the course of HR. Preoperatively, cinacalcet administration along with gradual increase in alphacalcidol dose, led to almost normalization of serum calcium and decrease in parathyroid hormone (PTH) concentrations. The patient underwent an uneventful subtotal parathyroidectomy, resulting in PTH normalization and stabilization of eucalcaemia during 18 months of follow-up. We conclude that, except for optimal dosage of elementary phosphate and alphacalcidol, cinacalcet prior to parathyroidectomy may be an effective option in patients with HR complicated with THP. PMID: 31475...
Source: Journal of Musculoskeletal Neuronal Interactions - September 3, 2019 Category: Neurology Tags: J Musculoskelet Neuronal Interact Source Type: research

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
This study aimed to assess the safety and effectiveness of cinacalcet in managing chronic dialysis patients with severe SHPT. METHODS: This retrospective study included 26 patients [age: 52 ± 12 years; 55% females; time on dialysis: 54 (4-236) months] on hemodialysis (N = 18) or peritoneal dialysis (N = 8) with severe SHPT (intact parathyroid hormone (iPTH) level> 600 pg/mL) and hyperphosphatemia and/or persistent hypercalcemia treated with cinacalcet. The patients were followed for 12 months. Their serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), and iPTH levels were measured at baseline and o...
Source: Jornal Brasileiro de Nefrologia - August 17, 2019 Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research

Enantioselective synthesis of (R)-Cinacalcet via cobalt-catalysed asymmetric Negishi cross-coupling.
Abstract A novel enantioselective synthesis of (R)-cinacalcet with 99% enantiomeric excesses (ee) has been achieved. The main strategies of the approach include a gram-scale cobalt-catalysed asymmetric cross-coupling of racemic ester with arylzinc reagent, Hoffman-type rearrangement of acidamide, the amidation of chiral amine, and improving the ee of chiral amide from 87% to 99% via recrystallization. PMID: 31310396 [PubMed - as supplied by publisher] (Source: Chirality)
Source: Chirality - July 16, 2019 Category: Molecular Biology Authors: Sun X, Wang X, Liu F, Gao Z, Bian Q, Wang M, Zhong J Tags: Chirality Source Type: research

An improved LC-MS/MS method for determination of cinacalcet in human plasma and its application to the evaluation of food intake effect on the pharmacokinetics of cinacalcet in healthy volunteers.
Abstract A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of cinacalcet in human plasma was developed and validated. This assay was based on the liquid-liquid extraction and cinacalcet-d4 was used as an internal standard (IS). Separation was achieved on a C18 column by the mobile phase A of water (containing 0.1% formic acid) and the mobile phase B of acetonitrile - water (95:5, V/V) (containing 0.2% formic acid) with the gradient elution. Quantification was done using multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 358.2&ra...
Source: Biomedical Chromatography : BMC - June 29, 2019 Category: Biomedical Science Authors: Li LL, Chen CL, Cai NF, Yi JL, Zheng C, Feng Y, Xiong WG, Luo X, Li WH, Cheng ZN Tags: Biomed Chromatogr Source Type: research

Clinical outcomes of parathyroidectomy versus cinacalcet in the clinical management of secondary hyperparathyroidism.
Authors: Kim WW, Rhee Y, Kim BS, Kim K, Lee CR, Kang SW, Lee J, Jeong JJ, Nam KH, Chung WY Abstract Parathyroidectomy (PTX) is the standard treatment for secondary hyperparathyroidism (SHPT); however, the administration of cinacalcet has gained prominence as a noninvasive treatment. We aimed to determine whether PTX or cinacalcet is more effective in preventing morbidity and mortality through reviewing follow-up data concerning surgical management of SHPT. We retrospectively analyzed and divided 209 patients with SHPT into two treatment groups: PTX (n = 78) and cinacalcet (n = 131) groups. We compared clinical feat...
Source: Endocrine Journal - June 15, 2019 Category: Endocrinology Tags: Endocr J Source Type: research

Bone matrix mineralization and osteocyte lacunae characteristics in patients with chronic kidney disease - mineral bone disorder (CKD-MBD).
Authors: Misof BM, Blouin S, Roschger P, Werzowa J, Klaushofer K, Lehmann G Abstract OBJECTIVES: Little is known about bone mineralization and osteocyte lacunae properties in chronic kidney disease mineral bone disorder (CKD-MBD). METHODS: In this retrospective study, we measured the bone mineralization density distribution (BMDD) and osteocyte lacunar section (OLS) 2D-characteristics by quantitative backscatter electron imaging in Straumann drill biopsy samples from n=58 patients with CKD-MBD. Outcomes were studied in relation to serum parathyroid hormone (PTH), alkaline phosphatase (APH), histomorphometric bo...
Source: Journal of Musculoskeletal Neuronal Interactions - June 14, 2019 Category: Neurology Tags: J Musculoskelet Neuronal Interact Source Type: research

Quality by Design Enabled Development of Oral Self-Nanoemulsifying Drug Delivery System of a Novel Calcimimetic Cinacalcet HCl Using a Porous Carrier: In Vitro and In Vivo Characterisation.
Abstract In this present research, work quality by design-enabled development of cinacalcet HCl (CH)-loaded solid self-nanoemulsifying drug delivery system (S-SNEDDS) was conducted using a porous carrier in order to achieve immediate drug release and better oral bioavailability. Capmul MCM (CAP), Tween 20 (TW 20) and Transcutol P (TRP) were selected as excipients. Cumulative % drug release at 30 min (Q30), emulsification times (ET), mean globule size (GS) and polydispersity index (PDI) were identified as critical quality attributes (CQAs). Factor mode effect analysis (FMEA) and Taguchi screening design were a...
Source: AAPS PharmSciTech - June 6, 2019 Category: Drugs & Pharmacology Authors: Panigrahi KC, Patra CN, Rao MEB Tags: AAPS PharmSciTech Source Type: research

Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience.
Authors: Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, Iiri T, Nangaku M, Makita N Abstract Primary hyperparathyroidism (PHPT) is a common endocrine disease. Although surgical treatment is curative in most cases, there are few alternative therapies for the hypercalcemia caused by PHPT. Cinacalcet is a positive allosteric modulator of the calcium sensing receptor and was conditionally approved in Japan in 2014 to treat PHPT cases. However, there have been few reports on the outcomes. In our present study, we investigated the efficacy and safety of cinacalcet in 61 PHPT patients who were treated with this agent at ...
Source: Endocrine Journal - May 18, 2019 Category: Endocrinology Tags: Endocr J Source Type: research

Complete Resolution of Tumoral Calcinosis in a Patient on Peritoneal Dialysis with Cinacalcet.
Authors: Hayat A PMID: 31088935 [PubMed - in process] (Source: Peritoneal Dialysis International)
Source: Peritoneal Dialysis International - May 16, 2019 Category: Urology & Nephrology Tags: Perit Dial Int Source Type: research

Brown tumor of the thoracic spine presenting with paraplegia in a patient with peritoneal dialysis
AbstractSecondary and tertiary hyperparathyroidism is an important problem of chronic kidney disease. Brown tumor is a benign, unusual, reactive lesion as a result of disturbed bone remodeling, from long-standing increase in parathyroid hormone level. Brown tumors may cause morbidity due to pressure symptoms on neural structures and spontaneous bone fractures. Herein, we presented a peritoneal dialysis patient with tertiary hyperparathyroidism under calcand calcitriol treatment for 4  years due to refusing of the parathyroidectomy operation. She admitted to hospital for sudden onset back pain with difficulty in gait a...
Source: CEN Case Reports - May 14, 2019 Category: Urology & Nephrology Source Type: research

NHE8 attenuates calcium influx into NRK cells and the proximal tubule epithelium.
Abstract To garner insight into the renal regulation of calcium homeostasis, we performed an mRNA micro-array on kidneys from mice treated with the calcium sensing receptor (CaSR) agonist cinacalcet. This revealed decreased gene expression of the sodium/proton exchanger isoform 8 (NHE8) in response to CaSR activation. These results were confirmed by quantitative real-time PCR. Moreover, administration of vitamin D also decreased NHE8 mRNA expression. In contrast, renal NHE8 protein expression from the same samples was increased. To examine the role of NHE8 in transmembrane calcium fluxes, we employed the normal ra...
Source: Am J Physiol Renal P... - May 1, 2019 Category: Urology & Nephrology Authors: Wiebe SA, Plain A, Pan W, O'Neill D, Braam B, Alexander RT Tags: Am J Physiol Renal Physiol Source Type: research

The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
CONCLUSIONS: The effectiveness of cinacalcet were still obviously demonstrated even in chronic HD patients with severe SHPT. In addition, the improvements of bone markers and FGF-23, and stabilization of vascular calcification were observed. Therefore, cinacalcet can provide salutary effects on CKD-MBD in severe SHPT and might be an initially effective PTH-lowering therapy prior to surgical parathyroidectomy as well as an alternative treatment in the patients unsuitable for surgery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT02056730. Date of registration: February 4, 2014. PMID: 31014177 [PubMed - in proc...
Source: Renal Failure - April 26, 2019 Category: Urology & Nephrology Tags: Ren Fail Source Type: research

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
ConclusionThis study shows the long-term efficacy and safety of evocalcet when orally administered to PD patients with SHPT once daily.Clinical trial registrationClinicalTrials.gov: NCT02549417,https://clinicaltrials.gov/ct2/show/NCT02549417; JAPIC: JapicCTI-153016,http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-153016. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - April 6, 2019 Category: Urology & Nephrology Source Type: research

Pharmacokinetics and pharmacodynamics of  cinacalcet in patients with renal failure receiving hemodialysis and hemodiafiltration therapy
.
CONCLUSION: Compared with healthy Chinese subjects, patients with renal failure had a higher Cmax and AUC0-24h, slightly prolonged time to Cmax (tmax) after administration of the same dose of cinacalcet. On HD treatment day, variation trends of iPTH in Chinese patients and healthy subjects were similar and significantly different from that on the HDF treatment day. Considering the high protein binding rate of cinacalcet, this may lead to the great free-drug clearance during HDF treatment.
. PMID: 30935461 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - April 4, 2019 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Challenges in the treatment of parathyroid carcinoma: a case report.
CONCLUSION: This is a very unusual patient with a newly discovered variant of the CDC73 gene and a phenotype characterized by recurrent PC, brown tumors, and N1a metastasized thyroid carcinoma. The present case confirms that PC may not exhibit clear malignant properties at first assessment, contributing to inadequate initial surgical treatment. Although infrequently, PC can be associated with papillary thyroid cancer. The diagnosis of brown tumor should be considered in patients with severe HPT and multiple destructive bone lesions mimicking metastases on PET/CT imaging. PMID: 30905030 [PubMed - as supplied by publishe...
Source: Hormones - March 27, 2019 Category: Endocrinology Tags: Hormones (Athens) Source Type: research

Calcium-sensing receptor activation attenuates collagen expression in renal proximal tubular epithelial cells.
Abstract Experimental studies showed that pharmacological activation of calcium-sensing receptor (CaSR) attenuated renal fibrosis in some animal models beyond modification of bone and mineral homeostasis; however, its underlying mechanisms remain largely unknown. Since excessive collagen deposition is the key feature of fibrosis, the present study aimed to examine whether CaSR was involved in the regulation of collagen expression in rats with adenine diet (AD)-induced renal fibrosis and in profibrotic TGF-β1-treated renal proximal tubular epithelial cells (PTECs). The results showed that the CaSR agonist cina...
Source: American Journal of Physiology. Renal Physiology - March 6, 2019 Category: Physiology Authors: Wu M, Feng Y, Ye GX, Han YC, Wang SS, Ni HF, Wang FM, Gao M, Lv LL, Liu BC Tags: Am J Physiol Renal Physiol Source Type: research

Correction to: An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28  days to & lt;  6 years with chronic kidney disease receiving dialysis
The original version of this article unfortunately contained three mistakes. In Table 1, the last line under “Key Inclusion Criteria” should read “Normal or clinically acceptable ECGs at screening and at day − 1.” In addition, the abbreviation “IP” in the legend to Table 1 stands for “investigational product.” (Source: Pediatric Nephrology)
Source: Pediatric Nephrology - February 25, 2019 Category: Urology & Nephrology Source Type: research

Sporadic primary hyperparathyroidism: medical and surgical updates.
Authors: Habib Z, Kabaker A, Camacho P Abstract This review discusses recent findings on the clinical presentation, evaluation, medical and surgical management of primary hyperparathyroidism. Medical management includes the use of cinacalcet and bisphosphonates for bone loss and correction of vitamin D deficiency. Surgical updates reviewed recent studies on the preoperative localization of the disease, specifically, sestamibi scans, 4DCT and MRI. Focused parathyroidectomy continues to be the preferred surgical approach for a select group of patients, guided by intraoperative use of PTH and new technology, such as e...
Source: Expert Review of Endocrinology and Metabolism - February 15, 2019 Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature
Journal Name: Journal of Pediatric Endocrinology and Metabolism Issue: Ahead of print (Source: Journal of Pediatric Endocrinology and Metabolism)
Source: Journal of Pediatric Endocrinology and Metabolism - February 7, 2019 Category: Endocrinology Source Type: research

Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature
Journal Name: Journal of Pediatric Endocrinology and Metabolism Volume: 32 Issue: 3 Pages: 305-310 (Source: Journal of Pediatric Endocrinology and Metabolism)
Source: Journal of Pediatric Endocrinology and Metabolism - February 7, 2019 Category: Endocrinology Source Type: research

Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study —A Comparison
Jacek Zawierucha, Jolanta Malyszko, Jacek S. Malyszko, Tomasz Prystacki, Wojciech P. Marcinkowski, Teresa Dryl-Rydzynska (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - February 5, 2019 Category: Endocrinology Source Type: research

Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism
Conclusion: In the present patients, long-term treatment with cinacalcet progressively decreased the total volume of parathyroid glands, as well as levels of intact PTH and phosphate in serum in a time-dependent manner. On the contrary, cinacalcet administration did not cause secondary failure or over-suppress the transition of parathyroid gland activity to hypoparathyroid status. These results suggest that cinacalcet treatment may postpone the need for parathyroidectomy and/or reduce its use even after long-term administration for up to 8 years.Nephron (Source: Nephron)
Source: Nephron - February 1, 2019 Category: Urology & Nephrology Source Type: research

Improved Control of Secondary Hyperparathyroidism in Hemodialysis Patients Switching from Oral Cinacalcet to Intravenous Etelcalcetide, Especially in Nonadherent Patients
Conclusions: Etelcalcetide was more effective than cinacalcet in this patient population, especially in the nonadherent subgroup, leading to better SHPT control without adverse effects.Blood Purif (Source: Blood Purification)
Source: Blood Purification - January 31, 2019 Category: Hematology Source Type: research

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis
This study had double-blind and open-label phases. Eligible patients aged 6 –
Source: Pediatric Nephrology - January 28, 2019 Category: Urology & Nephrology Source Type: research

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis
Conclusions: rs11063112 was associated with HF and cardiovascular mortality in patients receiving dialysis with moderate to severe secondary hyperparathyroidism.Am J Nephrol 2019;49:125 –132 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - January 22, 2019 Category: Neurology Source Type: research

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.
CONCLUSIONS: rs11063112 was associated with HF and cardiovascular mortality in patients receiving dialysis with moderate to severe secondary hyperparathyroidism. PMID: 30669147 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - January 22, 2019 Category: Urology & Nephrology Authors: Schwantes-An TH, Liu S, Stedman M, Decker BS, Wetherill L, Edenberg HJ, Vatta M, Foroud TM, Chertow GM, Moe SM Tags: Am J Nephrol Source Type: research

The use of cinacalcet for the treatment of calciphylaxis in patients with chronic kidney disease: A comprehensive review.
Abstract Calciphylaxis is a rare but life-threatening condition, most commonly affecting patients with stage 4 or 5 chronic kidney disease. No universally accepted therapy exists so far. In an attempt to avoid surgical intervention with parathyroidectomy, which is of questionable efficacy and carries several risks, a number of noninvasive treatments have been trialled with variable success. These treatments are aimed at modifying risk factors for calciphylaxis, in particular hypercalcaemia, hyperphosphataemia and hyperparathyroidism. The aim of this review was to summarise the available evidence to determine the p...
Source: The Australasian Journal of Dermatology - January 21, 2019 Category: Dermatology Authors: Deen J, Schaider H Tags: Australas J Dermatol Source Type: research

Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with End-stage Kidney Disease Receiving Maintenance Hemodialysis.
CONCLUSIONS: We found no evidence linking TMAO to adverse clinical outcomes in patients receiving maintenance hemodialysis with moderate to severe secondary hyperparathyroidism. PMID: 30665924 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - January 21, 2019 Category: Urology & Nephrology Authors: Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD Tags: Clin J Am Soc Nephrol Source Type: research

Variability in Cinacalcet Prescription across US Hemodialysis Facilities.
Abstract BACKGROUND AND OBJECTIVES: Calcimimetic drugs used to treat secondary hyperparathyroidism are being considered for inclusion in the Medicare ESRD Prospective Payment System bundle after an evaluation period. Understanding of utilization patterns of calcimimetics across dialysis facilities may help align financial incentives with clinical objectives. Our study's purpose was to describe the distribution of cinacalcet prescription across United States hemodialysis facilities and to explore factors that may influence cinacalcet utilization. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used month...
Source: Clinical Journal of the American Society of Nephrology : CJASN - January 21, 2019 Category: Urology & Nephrology Authors: Fuller DS, Xing S, Belozeroff V, Yehoshua A, Morgenstern H, Robinson BM, Rubin RJ, Bhatt N, Pisoni RL Tags: Clin J Am Soc Nephrol Source Type: research

GSE112831 Effect of cinacalcet HCL on gene expression in mouse kidney
Contributor : R T AlexanderSeries Type : Expression profiling by arrayOrganism : Mus musculusIn order to identify renal pathways regulated by activation of the calcium sensing receptor (CaSR) we performed a microarray on RNA isolated from kidneys of mice not treated or treated with conacalcet HCL (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - January 1, 2019 Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
Giulia Di Dalmazi, Cesidio Giuliani, Giorgio Napolitano (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - December 21, 2018 Category: Endocrinology Source Type: research

Discussion
Dr Sally E Carty (Pittsburgh, PA): Very nice study. Very well presented and very tactful. But I am going to try to draw you out. Do you think  Sensipar is bad for people? (Source: Surgery)
Source: Surgery - December 6, 2018 Category: Surgery Source Type: research